Regeneron Pharmaceuticals, Inc. (REGN)

624.02 -6.61 (-1.05%) As of 03:35PM EDT. Market open.

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 10,715

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Leonard S. Schleifer M.D., Ph.D.	Founder, Pres, CEO & Director	6.47M	446.39M	1953
Dr. George D. Yancopoulos M.D., Ph.D.	Scientific Founder, Pres, Chief Scientific Officer & Director	6.4M	172.02M	1960
Mr. Robert E. Landry Jr.	Exec. VP of Fin. & CFO	1.9M	3.48M	1964
Mr. Joseph J. LaRosa	Exec. VP, Gen. Counsel & Sec.	1.75M	23.23M	1959
Dr. Andrew J. Murphy Ph.D.	Exec. VP of Research	1.57M	19.76M	1959
Mr. Daniel P. Van Plew	Exec. VP and GM of Industrial Operations & Product Supply	1.77M	17.96M	1973
Ms. Patrice Gilooly	Sr. VP of Quality Assurance & Operations	N/A	N/A	N/A
Mr. Christopher R. Fenimore	Sr. VP, Head of Accounting & Controller	N/A	N/A	1971
Mr. Gerald Underwood	Sr. VP of Technical Operations	N/A	N/A	N/A
Mr. Bob McCowan	Sr. VP of IT & Chief Information Officer	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Corporate governance

Regeneron Pharmaceuticals, Inc.’s ISS governance QualityScore as of 31 July 2022 is 10. The pillar scores are Audit: 5; Board: 10; Shareholder rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.